Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Age of 18-70 years * Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer * Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy. * Patients with measurable lesions * Eatern Cooperative Oncolgy Group status 0 to 2. * Life expectancy \>/= 5 months * Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by 1. Absolute neutrophil count \>/= 1.5 x 10\^9/L, Platelet count \>/= 100 x 10\^9/L 2. Total bilirubin \</= upper limit of normal 3. Aspartate Aminotransferase and/or Alanine Aminotransferase \</= 2 x upeer limit of normal 4. creatinine \</= 1.5 x upeer limit of normal * Patients who have signed the informed consent form. Exclusion Criteria: * Female volunteers admitted to the study must be using a reliable means of contraception * Received radiation therapy within 6 weeks before randomization * Known brain or spinal cord metastases * Have acute infection * Have active infection or serious concomitant systemic disorder incompatible with the study * Presence or history of malignancy other than Non-Small Cell Lung Cancer * Have severe neurologic or psychological disorder * Patients who have to receive other chemo-radiotherapy or immunotherapy * Patients who have received chemotherapy within the previous 30 days * Patients who are candidates for combined modality treatment. * Patients who have participated in a clinical study within the previous 30 days